Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.
Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.
Has no product on sale, so it funds trials with money raised from investors, and revenue would start only with an approval or a licensing deal. A gene therapy is meant to be a one-time treatment, which is why such drugs are priced per patient rather than as a recurring prescription.
Moat: none (IP / patents). Addresses ultra-rare pediatric CNS diseases with no approved treatments, but is clinical-stage and cash-constrained.
Headquarters: Dallas, Texas, US · Founded: 2018 · Employees: 99
Size Taysha Gene Therapies (TSHA) is a United States Health Care company (Biotechnology) with a market value of $1.30B, the 2068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.99 on 18 Nov 2026.
Performance Over six months the shares fell 27.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 13.1% over the last twelve months (peer median +15.8%); the operating margin is -2,998.0% (peer median -38.9%).
Valuation It trades at 170.1× enterprise value to sales against a peer median of 8.4× (4th most expensive of 19).
Short interest Short interest is 16.4% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.49M | $9.77M | $8.33M | $15.5M | $2.50M |
| Revenue growth | — | +17% | -46% | +518% | — |
| Gross profit | $4.34M | $8.63M | $7.09M | $14.1M | $15,000 |
| EBITDA | -$163M | -$109M | -$85.4M | -$70.0M | -$124M |
| Net income | -$156M | -$109M | -$89.3M | -$112M | -$166M |
| Free cash flow | -$142M | -$93.8M | -$81.6M | -$76.9M | -$109M |
| Capital expenditure | $3.72M | $738,000 | $374,000 | $7.37M | $24.9M |
| Total debt | $54.6M | $70.5M | $64.0M | $61.1M | $59.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies TSHA | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a |
| PTC Therapeutics PTCT | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% |
| Sarepta Therapeutics SRPT | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% |
| uniQure QURE | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TSHA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.9% | -15.9% | 5th highest of 21 |
| 6-month return | -27.3% | -20.3% | 6th lowest of 20 |
| Distance from 52-week high | -45.3% | -48.1% | 9th highest of 21 |
| Revenue growth (TTM) | -13.1% | +15.8% | 4th lowest of 18 |
| Operating margin | -2,998.0% | -38.9% | 2nd lowest of 19 |
| EV / Sales | 170.1× | 8.4× | 4th most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |